Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables: 2019-2020

Historic Receivables for Seres Therapeutics (MCRB) over the last 2 years, with Dec 2020 value amounting to $17.6 million.

  • Seres Therapeutics' Receivables was N/A to $404,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year change of. This contributed to the annual value of $17.6 million for FY2020, which is 455.88% up from last year.
  • According to the latest figures from FY2020, Seres Therapeutics' Receivables is $17.6 million, which was up 455.88% from $3.2 million recorded in FY2019.
  • In the past 5 years, Seres Therapeutics' Receivables ranged from a high of $17.6 million in FY2020 and a low of $3.2 million during FY2019.
  • Moreover, its 2-year median value for Receivables was $10.4 million (2019), whereas its average is $10.4 million.
  • Data for Seres Therapeutics' Receivables shows a peak YoY spiked of 455.88% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows Seres Therapeutics' Receivables stood at $3.2 million in 2019, then spiked by 455.88% to $17.6 million in 2020.